• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

NVS OBU marketing - why are people leaving?

Quote








Anonymous said:
Afinitor, Sandostatin LAR, and Gleevic LoE's are coming. The Novartis Oncology luxury liner has hit its iceberg and is about to go down.
Click to expand...

The whole industry has hit an iceberg - it's now all about degrees of futility. NVS oncology is FAR stronger from a pipeline perspective than most pharma - especially Pfizer (what do they have in oncology anyway other than Sutent?). If you really want material improvement, try Genentech (but they probably would not hire anyone from NVS).
 








You may want to look at the Pfizer pipeline, they have a stronger and more reliable one than NVS. NVS has very limited patient populations in most of the upcoming pipeline drugs. And recent history show many of our pipeline drugs have died.
 








Anonymous said:
You may want to look at the Pfizer pipeline, they have a stronger and more reliable one than NVS. NVS has very limited patient populations in most of the upcoming pipeline drugs. And recent history show many of our pipeline drugs have died.
Click to expand...

You obviously need to do a little more homework on the Pfizer pipeline and recent history in oncology.
 




Top Bottom
Back
Quote